Abstract
In the last 20 years, microRNAs (miRNAs) have become the most promising class of diagnostic and prognostic biomarkers for human cancer. From a therapeutic perspective, advances in the understanding of the molecular role of miRNAs in the pathological processes have significantly influenced the selection of new therapeutic modalities. Moreover, the intrinsic characteristics that confer stability to miRNAs in vitro, allow a longer molecular/structural resistance and activity in vivo. Preclinical models have consistently underlined the feasibility and efficacy of miRNA-based therapies, either alone or in combination with current targeted therapies. The appealing strength of such therapeutic option dwells in miRNAs’ ability to concurrently target multiple genes, frequently in the context of a specific network/pathway. This property allows miRNA-based therapy to be extremely efficient in regulating distinct biological processes relevant to normal and pathological cell homeostasis. The purpose of this review is to summarize the role of miRNAs in gastrointestinal carcinogenesis and their potential use as novel biomarkers and therapeutics.
Keywords: Biomarkers, gastrointestinal carcinogenesis, locked nucleic acid, miRNAs, noncoding RNA, therapeutics.
Current Drug Targets
Title:MicroRNAs as Tools and Effectors for Patient Treatment in Gastrointestinal Carcinogenesis
Volume: 16 Issue: 4
Author(s): Edoardo D'Angelo, Caterina Vicentini, Marco Agostini, Andras Kiss, Raffaele Baffa, Aldo Scarpa and Matteo Fassan
Affiliation:
Keywords: Biomarkers, gastrointestinal carcinogenesis, locked nucleic acid, miRNAs, noncoding RNA, therapeutics.
Abstract: In the last 20 years, microRNAs (miRNAs) have become the most promising class of diagnostic and prognostic biomarkers for human cancer. From a therapeutic perspective, advances in the understanding of the molecular role of miRNAs in the pathological processes have significantly influenced the selection of new therapeutic modalities. Moreover, the intrinsic characteristics that confer stability to miRNAs in vitro, allow a longer molecular/structural resistance and activity in vivo. Preclinical models have consistently underlined the feasibility and efficacy of miRNA-based therapies, either alone or in combination with current targeted therapies. The appealing strength of such therapeutic option dwells in miRNAs’ ability to concurrently target multiple genes, frequently in the context of a specific network/pathway. This property allows miRNA-based therapy to be extremely efficient in regulating distinct biological processes relevant to normal and pathological cell homeostasis. The purpose of this review is to summarize the role of miRNAs in gastrointestinal carcinogenesis and their potential use as novel biomarkers and therapeutics.
Export Options
About this article
Cite this article as:
D'Angelo Edoardo, Vicentini Caterina, Agostini Marco, Kiss Andras, Baffa Raffaele, Scarpa Aldo and Fassan Matteo, MicroRNAs as Tools and Effectors for Patient Treatment in Gastrointestinal Carcinogenesis, Current Drug Targets 2015; 16 (4) . https://dx.doi.org/10.2174/1389450116666141210091454
DOI https://dx.doi.org/10.2174/1389450116666141210091454 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MiRNA-145 and Its Direct Downstream Targets in Digestive System Cancers: A Promising Therapeutic Target
Current Pharmaceutical Design Photosensitization of Biomolecules by Phenothiazine Derivatives
Current Drug Targets Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment
Current Pharmaceutical Design Cadherins: The Superfamily Critically Involved in Breast Cancer
Current Pharmaceutical Design Adrenoceptors: Non Conventional Target for Breast Cancer?
Current Medicinal Chemistry The Current Role of PET/CT in Radiotherapy Planning
Current Radiopharmaceuticals Preface
Current Pharmaceutical Design Quercetin in Cancer Treatment, Alone or in Combination with Conventional Therapeutics?
Current Medicinal Chemistry Targetting Esophageal and Gastric Cancers with Monoclonal Antibodies
Current Topics in Medicinal Chemistry Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology Molecular Targets for Nutritional Preemption of Cancer
Current Cancer Drug Targets The Modulation of Pain by Metabotropic Glutamate Receptors 7 and 8 in the Dorsal Striatum
Current Neuropharmacology Molecular Imaging of Therapeutic Potential of Reporter Probes
Current Drug Targets Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence
Current Pharmaceutical Design Optimization of the Enzymolysis Conditions for Scorpion Peptides and Evaluation of its Antitumor Activity
Current Signal Transduction Therapy Antitumor Therapeutic Strategies Based on the Targeting of Epidermal Growth Factor-Induced Survival Pathways
Current Drug Targets Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued) Rikkunshito and Ghrelin Secretion
Current Pharmaceutical Design Anticancer Effect of Amygdalin (Vitamin B-17) on Hepatocellular Carcinoma Cell Line (HepG2) in the Presence and Absence of Zinc
Anti-Cancer Agents in Medicinal Chemistry